Seagen Inc.

• A Study of Disitamab Vedotin Alone and with Pembrolizumab in Urothelial Cancer That Expresses HER2 Not authorised
  2022-500030-28-00 Phase II 4 countries DISITAMAB VEDOTIN; PEMBROLIZUMAB
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting
  2023-504445-31-00 Phase II 4 countries DISITAMAB VEDOTIN
• A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting
  2023-507555-29-00 Phase I/II 4 countries DISITAMAB VEDOTIN; TUCATINIB
• Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting
  2022-501105-12-00 Phase III 13 countries DISITAMAB VEDOTIN; PEMBROLIZUMAB
• A Study of Disitamab Vedotin Alone or with Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting
  2022-500030-28-01 Phase II 4 countries DISITAMAB VEDOTIN
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 Phase I 6 countries
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 Phase III 14 countries BEVACIZUMAB; CETUXIMAB; TRASTUZUMAB; TUCATINIB
• A Safety Study of PF-08046040/SEA-CD70 in Patients with Myeloid Malignancies Recruiting
  2023-506945-42-00 Phase I 1 country
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors Recruiting
  2023-508469-34-00 Phase I 2 countries
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended
  2023-503827-25-01 Phase III 13 countries SIGVOTATUG VEDOTIN
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended
  2023-503826-37-00 Phase III 12 countries TRASTUZUMAB, PERTUZUMAB; TUCATINIB
• Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended
  2023-503384-41-00 Phase III 7 countries LENALIDOMIDE
• A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast… Ended
  2024-514733-38-00 Phase III 8 countries TRASTUZUMAB EMTANSINE; TUCATINIB
• An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat… Ended
  2023-503421-19-00 Phase III 10 countries CARBOPLATIN; CISPLATIN; ENFORTUMAB VEDOTIN; GEMCITABINE; PEMBROLIZUMAB
• Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Ended
  2023-503812-34-00 Phase II 4 countries PEMBROLIZUMAB; TISOTUMAB VEDOTIN
• A study of PF-08046050 (SGN-CEACAM5C) in adults with advanced solid tumors Halted
  2023-505858-18-00 Phase I 4 countries
• A safety study of PF-08046044/SGN-35C in adults with advanced cancers Ended
  2023-505813-26-00 Phase I 5 countries
• A safety study of PF-08046045/SGN-35T in adults with advanced cancers Ended
  2022-502390-41-00 Phase I 4 countries
• A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Ended
  2022-502348-11-00 Phase I 3 countries
• A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors Ended
  2022-500094-14-00 Phase I 3 countries SGN-ALPV
• A Study of SGN-B7H4V in Advanced Solid Tumors Ended
  2023-503389-22-00 Phase I 4 countries
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 Phase III 13 countries BRIMONIDINE TARTRATE; DEXAMETHASONE; DEXTRAN 70, HYPROMELLOSE; TISOTUMAB VEDOTIN
• A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC). Ended
  2023-503388-40-00 Phase I (Other) 3 countries
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Ended
  2023-503387-16-00 Phase II 4 countries BRENTUXIMAB VEDOTIN; DACARBAZINE; DOXORUBICIN HYDROCHLORIDE; NIVOLUMAB

Showing 1–24 of 27 trials